Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-26481585 + bortezomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral, Intravenous (bortezomib), Oral (dexamethasone)
01
Overview
A combination therapy composed of **JNJ-26481585 (quisinostat)**, a potent oral pyrimidyl-hydroxamic acid class histone deacetylase (HDAC) inhibitor with high activity against class I and II HDAC isoforms; **bortezomib**, a proteasome inhibitor; and **dexamethasone**, a synthetic glucocorticoid. **JNJ-26481585** disrupts aberrant histone deacetylation to induce apoptosis and growth arrest in cancer cells. **Bortezomib** inhibits the 26S proteasome, affecting protein degradation pathways crucial for myeloma cell survival. **Dexamethasone** induces apoptosis in lymphoid cells and has anti-inflammatory effects. The regimen is investigated in relapsed/refractory multiple myeloma and other cancers, with preclinical and clinical evidence suggesting synergistic antitumor effects.
- Brand names
- quisinostat
- Other names
- JNJ26481585JNJ-26481585JNJ 26481585JNJ-26481585 + bortezomib + dexamethasone
02
Targets
HDAC2 (Histone deacetylase 2)GR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)NF-κBPSMB5 (Proteasome subunit beta Type-5)HDAC3 (Histone Deacetylase 3)
Beyond the preview
Go deeper on JNJ-26481585 + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-26481585 + bortezomib + dexamethasone.